Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2012

Open Access 01-12-2012 | Research article

Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials

Authors: Jingxu Sun, Yongxi Song, Zhenning Wang, Peng Gao, Xiaowan Chen, Yingying Xu, Jiwang Liang, Huimian Xu

Published in: BMC Cancer | Issue 1/2012

Login to get access

Abstract

Background

In this meta-analysis we aimed to determine the effectiveness and safety of hyperthermic intraperitoneal chemotherapy (HIPC) for patients with advanced gastric cancer who underwent gastrectomy.

Methods

In accordance with standard meta-analysis procedures, our study included patients who underwent resection for advanced gastric cancer and were randomly allocated to receive either hyperthermic intraperitoneal chemotherapy or control. We searched PubMed (up to November 2011), EMBASE (up to November 2011), Cochrane Database of Systematic Reviews (CDSR), and Cochrane Central Register of Controlled Trials (CCTR) (up to November 2011). Both published and unpublished trials were included in the analysis, and no search restrictions were imposed. There was no language restriction. The results were analyzed using RevMan 5.1 software, which was provided by Cochrane Collaboration.

Results

There were ten randomized controlled trials included in the analysis. A total of 1062 patients with gastric cancer in these studies were divided into the HIPC group (n = 518) and control group (n = 544). A significant improvement in survival was observed in the HIPC groups compared to the control group in the mitomycin C (MMC) subgroup (RR = 0.75, 95%CI 0.65-0.86; P < 0.00001) and the 5-FU group (RR = 0.69, 95%CI 0.52-0.90; P < 0.00001); the total RR was 0.73 (95%CI 0.64-0.83; P < 0.00001). Our findings indicated that HIPC potentially exhibited a lower peritoneal recurrence rate in the HIPC group compared to the control group (RR = 0.45, 95%CI 0.28-0.72; P = 0.001).

Conclusions

Our meta-analysis demonstrated that HIPC may improve the overall survival rate for patients who receive resection for advance gastric cancer potentially, and help to prevent peritoneal local recurrence among patients with serosal invasion in gastric cancer.
Appendix
Available only for authorised users
Literature
1.
Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Neqri E, Malvezzi M, La VC: Recent patterns in gastric cancer: A global overview. Int J Cancer. 2009, 125: 666-673. 10.1002/ijc.24290.CrossRefPubMed
2.
Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin. 2005, 55 (2): 74-108. 10.3322/canjclin.55.2.74.CrossRefPubMed
3.
4.
5.
Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, et al: Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000, 88: 358-363. 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O.CrossRefPubMed
6.
Roviello F, Marrelli D, Manzoni GD, Morqaqni P, Di Leo A, Saraqoni L, De Stefano A: Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003, 90: 1113-1119. 10.1002/bjs.4164.CrossRefPubMed
7.
Yamada E, Miyaishi S, Nakazato H: The surgical treatment of cancer of the stomach. Int Surg. 1980, 65: 387-399.PubMed
8.
Yan TD, Black D, Suqarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL: A systematic review and meta-analysis of the randomized controlled trials on adjuvant intra-peritoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007, 14: 2702-2713. 10.1245/s10434-007-9487-4.CrossRefPubMed
9.
Sugarbaker PH, Yu W, Yonemura Y: Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: The evolution of treatment strategies for advanced gastric cancer. Semin Surg Oncol. 2003, 21: 233-248. 10.1002/ssu.10042.CrossRefPubMed
10.
Xu DZ, Zhan YQ, Sun XW, Cao SM, Geng QR: Meta-analysis of intraperitoneal chemotherapy for gastric cancer. World J Gastroenterol. 2004, 10 (18): 2727-2730.CrossRefPubMedPubMedCentral
11.
Shiu MH, Fortner JG: Intraperitoneal hyper-thermic treatment of implanted peritoneal can-cer in rats. Cancer Res. 1980, 40: 4081-4084.PubMed
12.
Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J: Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980, 40: 256-260.PubMed
13.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4.CrossRefPubMed
14.
Cochran WG: The combination of estimates from different experiments. Biometrics. 1954, 10: 101-129. 10.2307/3001666.CrossRef
15.
16.
Koga S, Hamazoe R, Maeta M, Shimizu N, Murakami A, Wakatsuki T: Prophylactic cancer therapy for peritoneal recurrence of gastric by continuous hyperthermic peritoneal perfusion with Mitomycin C. Cancer. 1988, 61 (2): 232-237. 10.1002/1097-0142(19880115)61:2<232::AID-CNCR2820610205>3.0.CO;2-U.CrossRefPubMed
17.
Hamatoe R, Maeta M, Kaibara N: lntraperitoneal thermochemotherapy for prevention of peritoneal recurrence of gastric cancer. Cancer. 1994, 73 (8): 2048-2052. 10.1002/1097-0142(19940415)73:8<2048::AID-CNCR2820730806>3.0.CO;2-Q.CrossRef
18.
Fujimura T, Yonemura Y, Muraoka K, et al: Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. Wrold J Surg. 1994, 18 (1): 150-155. 10.1007/BF00348209.CrossRef
19.
Ikeguch M, Kondou A, Oka A, et al: Effects of continuous hyperthermic peritoneal perfusion on prognosis of gastric cancer with serosal invasion. Eur J Surg. 1995, 161 (8): 581-586.
20.
Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T: Successful intra-peritoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer. 1999, 85: 529-554. 10.1002/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>3.0.CO;2-9.CrossRefPubMed
21.
Yonemura Y, de Aretxabala X, Fujimura T, et al: Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: final results of a randomised controlled study. Hepatogastroenterol. 2001, 48: 1776-1782.
22.
Zuo Y, Xu M, Shen D, Lu JF: Postoperative intraperitionealhyperthermic chemoperfusion combined with intravenous chemotherapy for 82 advanced gastric cancer patients. Zhonghua Zhongliu Zazhi. 2004, 26: 247-249.PubMed
23.
Wei G, Fang GE, Bi JW, Shen XJ, Nie MM, Xue XC, Hua JD: Efficacy of intraoperative hypotonic peritoneal chemo-hyperthermia combined with early postoperative intraperitoneal chemotherapy on gastric cancer. Ai Zheng. 2005, 24: 478-482.PubMed
24.
Zhang GY, Chen XC, Pan K, Xia LG, Zuo M, Zheng T: Application of hyperthermic intraoperitoneal chemotherapy in patients with gastric cancer. Zhonghua Wei Chang Waike Zazhi. 2007, 10 (4): 362-364.
25.
Deng HJ, Wei ZG, Zhen L, Li GX, Uang XC, Qing SH: Clinical application of perioperative continuous hyperthermic peritoneal perfusion chemotherapy for gastric cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2009, 29 (2): 295-297.PubMed
26.
Kim JY, Bae HS: A controlled clinical study of serosa-invasive gastric carcinoma patients who underwent surgery plus intraperitoneal hyperthermo-chemo-perfusion (IHCP). Gastric Cancer. 2001, 4: 27-33. 10.1007/s101200100013.CrossRefPubMed
27.
Sugarbaker PH: Management of Gastric Cancer. 1991, Boston: Kluwer Academic Publisher, 277-284.
28.
Weisberger AS, Levine B, Storaasli JP: Use of nitrogen mus-tard in treatment of serous effusions of neoplastic origin. JAMA. 1955, 159: 1704-1707. 10.1001/jama.1955.02960350004002.
29.
30.
MacDonald JS, Malley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001, 345: 725-729. 10.1056/NEJMoa010187.CrossRefPubMed
31.
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scrarffe JH, Lofts FJ, Falk SJ, Iveson TJ, et al: Perioperative chemotherapy versus surgery alone for resectable gastro-esophageal cancer. N Engl J Med. 2006, 355: 11-20. 10.1056/NEJMoa055531.CrossRefPubMed
32.
Kazuo H, Kanji K, Atsushi I, Yamaquchi A, Nakaqawara G, Umeda S, Kusaka Y: Efficacy of Continuous Hyperthermic Peritoneal Perfusion for the Prophylaxis and Treatment of Peritoneal Metastasis of Advanced Gastric Cancer: Evaluation by Multivariate Regression Analysis. Oncology. 1999, 57: 106-114. 10.1159/000012016.CrossRef
33.
Sugarbaker PH: Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998, 14 (3): 254-261. 10.1002/(SICI)1098-2388(199804/05)14:3<254::AID-SSU10>3.0.CO;2-U.CrossRefPubMed
Metadata
Title
Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials
Authors
Jingxu Sun
Yongxi Song
Zhenning Wang
Peng Gao
Xiaowan Chen
Yingying Xu
Jiwang Liang
Huimian Xu
Publication date
01-12-2012
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2012
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-12-526

Other articles of this Issue 1/2012

BMC Cancer 1/2012 Go to the issue

Case report

Intraneural metastasis of gastric carcinoma leads to sciatic nerve palsy

Case report

Pyloric gland adenoma of the cystic duct with malignant transformation: report of a case with a review of the literature

Research article

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

Research article

Deletion of the TNFAIP3/A20gene detected by FICTION analysis in classical Hodgkin lymphoma

Research article

Neck control after definitive radiochemotherapy without planned neck dissection in node-positive head and neck cancers

Research article

Development of a gene therapy strategy to target hepatocellular carcinoma based inhibition of protein phosphatase 2A using the α-fetoprotein promoter enhancer and pgk promoter: an in vitro and in vivo study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits